The Trans Conjunctival Sutureless Vitrectomy (TSV) technology, a sutureless solution for Diabetic Retinopathy, a commonly found complication among diabetics was introduced here at the Aditya Jyot Eye Hospital, Mumbai by Bausch & Lomb, the global leader in eye care.
The landmark technique was introduced on occasion of World Health Day by Dr. Mark Humayun, one of the innovators of Bausch & Lomb’s new Trans-Conjunctival Sutureless Vitrectomy (TSV) Technology for Diabetic Retinopathy. Dr. Humayun performed live demonstration of the TSV technology in association with Dr. S. Natrajan of the Aditya Jyot Eye Hospital, where this facility was made available.
The surgery was followed by a scientific programme, which provided a platform to the Indian ophthalmic community to discuss the intricacies of the revolutionary TSV technology with Dr. Humayun, one of the developers of the TSV technology and a professor at the Doheny Eye Institute at USC School of Medicine, USA.
“It is our pleasure to join hands with Dr. Mark Humayun & Bausch & Lomb in showcasing the benefits of the TSV technology to the ophthalmic community and to the general public” said Dr. S. Natrajan, medical director, Aditya Jyot Eye Hospital on the new introduction. Adding further he said, “It is encouraging that corporates like Bausch & Lomb are bringing advanced technologies like TSV almost at the same time as their global introduction. We look forward to harness the edge provided by the technology to further improve the quality of treatment for our patients.”
Diabetic retinopathy is a complication of diabetes and a leading cause of blindness. It occurs when diabetes damages the tiny blood vessels inside the retina (the light-sensitive tissue at the back of the eye) and the complications can include weakening of blood vessel walls or leakage from blood vessels. Diabetic retinopathy may not cause any noteworthy changes to one’s vision initially but over time, it can get worse and can even cause vision loss.
All people with type 1 and type 2 diabetes are at risk of getting diabetic retinopathy. According to independent research studies, between 40 to 45 percent of Americans diagnosed with diabetes were found to be at some stage of diabetic retinopathy. The studies also indicate that nearly all patients who have type 1 diabetes for about 20 years will have evidence of diabetic retinopathy.
The TSV technology offers enormous benefits for the patients. Not only is the recovery time much faster, the technology also considerably reduces any risks of infections.